A combination of photodynamic therapy and chemotherapy displays a differential cytotoxic effect on human metastatic melanoma cells

- Treatment of dacarbazine and PDT to overcome melanoma resistance, is proposed.
- Synergism of dacarbazine and PDT exists in reducing melanoma cell viability.
- Morphological disruption was observed upon PDT only and PDT + Dacarbazine treatments.
- ABCG2 transporters contribute to decreasing the self-renewal capacity of melanoma.

BackgroundCutaneous melanoma represents the most lethal form of skin cancer and remains refractory to current therapies. Failure of treatment has been attributed to the over-expression of ABC transporters which efflux the drugs, below their cytotoxic threshold within cells. Therefore, this study set to investigate; the efficacy of a combinatorial approach comprising chemotherapy (Dacarbazine) and photodynamic therapy (PDT) to overcome resistance in pigmented and unpigmented metastatic melanoma and potentially identify resistant mechanisms.MethodsThe cytotoxic effect of the chemotherapy, PDT and combination therapy treatment (Dacarbazine + PDT) was determined using a cell viability XTT assay. Thereafter, melanoma cells morphology, self-renewal capacity and ABCG2 protein expression, were determined using fluorescence microscopy, clonogenic assay, western blot and flow cytometry. All results were analyzed by t-test and ANOVA, followed by individual comparisons with post-tests.ResultsThis study describes possible synergism of PDT + DTIC in reducing melanoma cell viability in vitro. At 24 h post-treatment, only the unpigmented melanomas were sensitive to DTIC treatment (20-25% death at 1.25 mM). At 48 h, a lethal dose of 50% was reached in these cells in contrast to the pigmented melanoma (20% at 48 h). The same trend was observed with the combination therapy (DTIC + PDT) at both time points. Furthermore, complete morphological disruption could be observed upon PDT only and PDT + DTIC treatments. Moreover, PDT and DTIC + PDT suppressed the self-renewal capacity of both melanoma cell lines. No significant differences in ABCG2 protein expression was found at 24 h post-treatment.ConclusionOverall, these results suggest that human melanomas remain heterogeneous in their phenotypes. Moreover, in our metastatic melanoma cells, ABCG2 transporters did not seem to be involved in resistance to therapies. Significantly though, a combinatorial approach of PDT and chemotherapy significantly decreases the self-renewal capacity of metastatic melanoma cells and could be a suggested adjunctive approach to post-resection treatment regimes.